Comments
Sun Pharmaceutical Industries today said its subsidiary has received approval from the US health regulator to market the generic version of GSK’s Coreg CR, extended release capsules in the American market.
One of the company’s wholly-owned subsidiaries has received final approval from the US Food and Drug Administration (USFDA) for the generic product in strengths of 10mg, 20mg, 40mg and 80 mg, Sun Pharma said in a statement.
Coreg CR extended release capsules are indicated for treating various heart conditions, including heart failure and high blood pressure.
According to IMS, Coreg CR had annual sales of around $208 million in the US for the 12 months ended August 2017.
Sun Pharma shares were trading 2.32 per cent up at Rs 535.40 apiece on BSE today.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.